Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: A 12-week prospective, open-label study

BMC Psychiatry

Volumn 12, Issue , 2012, Pages

  Miyaoka, Tsuyoshi ^a   Wake, Rei ^a   Furuya, Motohide ^a   Liaury, Kristian ^a   Ieda, Masa ^a   Kawakami, Kazunori ^a   Tsuchie, Keiko ^a   Inagaki, Takuji ^a   Horiguchi, Jun ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Asperger's disorder; Irritability; Pervasive developmental disorder not otherwise specified; Yokukansan (TJ 54)

Indexed keywords

HERBACEOUS AGENT; TJ 54; UNCLASSIFIED DRUG; YOKUKANSAN; KAMPO; PSYCHOTROPIC AGENT;

ABERRANT BEHAVIOR CHECKLIST IRITABILITY SUBSCALE SCORE; ADOLESCENT; ADULT; AGGRESSION; ANGER; ARTICLE; ASPERGER SYNDROME; AUTOMUTILATION; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERACTIVITY; INTELLIGENCE QUOTIENT; IRRITABILITY; LETHARGY; MALE; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRESCHOOL CHILD; PROSPECTIVE STUDY; PSYCHOSOCIAL WITHDRAWAL; SCHOOL CHILD; SCORING SYSTEM; SPEECH DISORDER; STEREOTYPY; BEHAVIOR DISORDER; BORDERLINE STATE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DEMENTIA; DRUG SAFETY; HERBAL MEDICINE; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPTIMAL DRUG DOSE; RISK ASSESSMENT; SOCIAL STATUS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ASPERGER SYNDROME; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870054486     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-12-215     Document Type: Article

References (46)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, Washington D.C. and London, England, 4th, Text Revision, American Psychiatric Association.
2. Stigler KA, Posey DJ, MeDougle CJ. Recent advance in the pharmacotherapy of autism. Expert Rev Neurotherapeutics 2002, 2:499-510.
3. Towbin KE. Pervasive developmental disorder not otherwise specified. Handbook of autism and pervasive developmental disorders 2005, 165-200. New York: John Wiley & Sons, Volkmar FR, Paul R, Klin A, Cohen D.
4. McDougle CJ, Posey DJ, Stigler KA. Pharmacological treatments. Understanding autism: from basic neuroscience to treatment 2006, 417-442. Boca Raton: CRC Press, Moldin SO, Rubenstein JLR.
5. Fombonne E. Epidemiology of autistic disorder and other pervasive developmental disorders. J Clin Psychiatry 2005, 66(Suppl 10):3-8.
6. Fombonne E. Epidemiological of pervasive developmental disorders. Pediatr Res 2009, 65:591-598. 10.1203/PDR.0b013e31819e7203, 19218885.
7. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006, 16:549-560. 10.1089/cap.2006.16.549, 17069544.
8. Correll CU, Carlson HE. Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006, 45:771-791. 10.1097/01.chi.0000220851.94392.30, 16832314.
9. Aman MG, Arnold LE, McDougle CJ, Vitiello B, Scahill L, Davies M, McCracken JT, Tierney E, Nash PL, Posey DJ, Chuang S, Martin A, Shah B, Gonzalez NM, Swiezy NB, Ritz L, Koenig K, McGough J, Gjuman JK, Lindsay RL. Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 2005, 25:565-569.
10. Anderson GM, Scahill L, McGracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B. Effects of short- and long-term risperidone treatment on prolactin levels in children and adolescents with autism. Biol Psychiatry 2007, 61:545-550. 10.1016/j.biopsych.2006.02.032, 16730335.
11. Barzman DH, DelBello MP, Kowatch RA, Garnert B, Fleck DE, Pathak S, Rappaport K, Delgado SV, Cmpbell P, Strakowski SM. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorder: A retrospective chart review. J Child Adolesc Psychopharmacol 2004, 14:593-600. 10.1089/cap.2004.14.593, 15662152.
12. Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004, 65:1531-1536. 10.4088/JCP.v65n1115, 15554768.
13. Finding RL, McNamara N, Gracious BL, O'Riordan MA, Reed MD, Demeter C, Blumer JL. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004, 14:287-294. 10.1089/1044546041649129, 15319025.
14. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 2005, 35:387-391. 10.1007/s10803-005-3306-1, 16119479.
15. Stigler KA, Posey DJ, McDougle CJ. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004, 14:455-463. 10.1089/cap.2004.14.455, 15650503.
16. Logan K, Wink MD, Craig A, Erickson MD, Christopher J, McDougle MD. Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders. Curr Treat Options Neurol 2010, 12:529-538. 10.1007/s11940-010-0091-8, 20848330.
17. Aizawa R, Kanbayashi T, Saito Y. Effects of yoku-kan-san-ka-chipi-hange on the sleep of normal healthy adult subjects. Psychiatry Clin Neurosci 2002, 56:303-304. 10.1046/j.1440-1819.2002.01006.x, 12047606.
18. Iwasaki K, Maruyama M, Tomita N, Furukawa K, Nemoto M, Fujiwara H, Seki T, Fujii M, Kodama M, Arai H. Effects of traditional Chinese herbal medicine Yi-gan san for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. J Clin Psychiatry 2005, 16:12-13.
19. Tahara E, Shimizu T, Moriyama K. Two cases with positive symptoms by dementia of elderly successfully treated with yokukan-san (in Japanese, abstract in English). Kampo-no-Rinsho; 2003, 1:105-114.
20. Iwasaki K, Satoh-Nakagawa T, Maruyama M. A randomized observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005, 66:248-252. 10.4088/JCP.v66n0214, 15705012.
21. Miyaoka T, Furuya M, Yasuda H, Hayashida M, Inagaki T, Hoiriguchi J. Ti-gan san for treatment of borderline personality disorder: an open-label study. Prog Neuropsychopharm & Biol Psychiatry 2008, 32:150-154. 10.1016/j.pnpbp.2007.07.026, 23197468.
22. Miyaoka T, Furuya M, Yasuda H, Hayashida M, Ingaki T, Horiguchi J. Yi-gansan for treatment of neuroleptic-induced tardive dyskinesia: an open-label study. Prog Neuropsychopharm & Biol Psychiatry 2008, 32:761-764. 10.1016/j.pnpbp.2007.12.003, 23197468.
23. Miyaoka T, Furuya M, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Charles Bonnet syndrome: successful treatment of visual hallucinations due to vision loss with Yi-gan san. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:382-383. 10.1016/j.pnpbp.2008.12.005, 19141308.
24. Miyaoka T, Furuya M, Yasuda H, Hayashida M, Nishida A, Insagaki T, Horiguchi J. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study. Clin Neuopharmacol 2009, 32:6-9.
25. Miyaoka T, Horiguchi J. Clinical potential of Yi-gan san (Yokukansan) for psychiatric disorders. Curr Psychiatry Rev 2009, 5:271-275.
26. Miyaoka T, Furuya M, Kristian L, Wake R, Kawakami K, Nagahama M, Kawano K, Ieda M, Tsuchie K, Horiguchi J. Yi-gan san for treatment of Charles Bonnet syndrome (visual hallucination due to vision loss): An open-label study. Clin Neuropharmacol 2011, 34:24-27. 10.1097/WNF.0b013e318206785a, 21164340.
27. First MB, Rl S, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders 1995, 1995. New York: American Psychiatric Press.
28. First MB. Structured clinical interview for DSM-IV axis II personality disorders (SCID-II) 1997, Washington, DC: American Pyschiatric Publishing.
29. Wechsler D. Wechsler intelligence scale for children 1999, San Antonio (Texas): Psychological Corporation, 3rd.
30. Guy W. ECDEU assessment manual for psychopharmacogy-revised 1976, 218-222. Rockville, MD, U.S.: Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs.
31. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985, 89:485-491.
32. Aman MG, Singh NN. Supplement to aberrant behavior checklist manual 1994, East Aurora (New York): Slosson Educational Publications.
33. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347:314-321. 10.1056/NEJMoa013171, 12151468, Research Units on Pediatric Psychopharmacology (RUPP) Autism Network.
34. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005, 162:1361-1369. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network.
35. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone treatment of disruptive behavioral symptoms in children with austic and other pervasive developmental disorders. Pediatrics 2004, 114:e634-641. 10.1542/peds.2003-0264-F, 15492353.
36. Brown EC, Aman MG, Harecamp SM. Factor analysis and norms on parent rating with the aberrant behavior checklist: community for young people in social education. Res Dev Disabil 2002, 23:45-60. 10.1016/S0891-4222(01)00091-9, 12071395.
37. Bartko JJ, Carpenter WT. On the methods and theory of reliability. J Nerv Ment Dis 1976, 163:307-317. 10.1097/00005053-197611000-00003, 978187.
38. Greenhill LL, Vitiello B, Fisher P, Levien J, Davies M, Abikoff H, Crisman AK, Chauan S, Finding RL, March J, Scahill L, Walkup J, Riddle MA. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in periatric psychopharmacology. J Am Acad Child Adlesc Psychiatry 2009, 43:1488-1496.
39. Kanno H, Sekiguchi K, Yamaguchi T, Terawaki K, Yuzurihara M, Kase Y, Ikarashi Y. Effect of yokukansan, a traditional Japanese medicine, on social and aggressive behavior of para-chloro amphetamine-injected rat. J Pharm Pharmacol 2009, 61:1249-1256.
40. Liao JF, Jan YM, Huang SY. Evaluation with receptor binding assay on the water extracts of ten CNS-active Chinese herbal drugs. Proc Natl Sci Counc Repub China B 1995, 19:151-158.
41. Nishi A, Yamaguchi T, Sekiguchi K, Ikarashi Y, Kase Y. Ameliorative effect of yokukansan an aggressive behavior in social isolated mice 2010, 176. London, England: The 40th Annual Meeting of Japanese Society of Neuropsychopharmacology, Abstract.
42. Shimada Y, Goto H, Itoh T. Evaluation of the protective effects of alkaloids isolated from the hooks and stems of uncaria sinesis on glutamate-induced neuronal death in cultured cerebellar granule cells from rats. J Pharm Pharmcol 1999, 51:715-722.
43. McDougle CJ, Erickson CA, Stigler KA, Posey DJ. Neurochemistry in the pathophysiology of autism. J Clin Psychiatry 2005, 66(Suppl):9-18.
44. Dawson G, Webb S, Shellenberg GD, Dager S, Friedman S, Aylward E, Richards T. Defining the broader phenotype of autism: genetic, brain, and behavioral perspectives. Dev Psychopathol 2002, 14:581-611.
45. Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005, 34:215-220.
46. Lord C, Ruter M, Le Couteur AM. Autism diagnostic interview revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev 1994, 24:659-685.